Statins : (Record no. 59703)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 07207nam a22004573i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC3018501 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729124102.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2008 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781608763450 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781606921036 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC3018501 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL3018501 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr10660362 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)923658434 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM666.S714 -- S728 2008eb |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615/.718 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Holmqvist, Gunnar N. |
| 245 10 - TITLE STATEMENT | |
| Title | Statins : |
| Remainder of title | Indications and Uses, Safety and Modes of Action. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Hauppauge : |
| Name of producer, publisher, distributor, manufacturer | Nova Science Publishers, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2008. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2008. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (219 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- STATINS: INDICATIONS AND USES, SAFETY AND MODES OF ACTION -- STATINS: INDICATIONS AND USES, SAFETY AND MODES OF ACTION -- CONTENTS -- PREFACE -- Chapter 1 STATIN THERAPY FOR CORONARY ARTERY DISEASE BEYOND LIPID LOWERING EFFECT -- ABSTRACT -- INTRODUCTION -- PREVENTION OF CORONARY EVENTS BY STATINS IN CLINICAL TRIALS -- STATINS' LIPID-INDEPENDENT EFFECTS FOR VASCULAR FAILURE -- Statins' Actions for Vascular Endothelial Dysfunction -- Clinical Assessment of Vascular Endothelial Function and Statins' Effects -- Vascular Smooth Muscle Dysfunction and Statin -- Inflammation in the Process of Atherosclelosis -- Anti-Inflammatory Actions of Statins -- Oxidative Stress in Athergenesis -- Anti-Oxydative Effects of Statins -- Effects of Statins on Platelets Activation and Thrombogenesis -- Effects of Statins on Neovascularization -- Effects of Statins on Myocardial Protection -- FUTURE ASPECTS OF STATIN THERAPY FOR CORONARY ARTERY DISEASE -- REFERENCES -- Chapter 2 SIDE EFFECTS OF STATINS IN MONOTHERAPY -- ABSTRACT -- INTRODUCTION -- THE PROBLEM -- TYPES OF ADVERSE EVENTS -- 1. Liver Function -- 2. Renal Function -- 3. Erectile Dysfunction -- 4. Muscular Problems -- Mechanisms: -- The role of exercise: -- Oxidation: -- a) LDL-oxidation: -- b) Isoprostanes: -- 5. Arthritis -- 6. Lupus-Like Syndrome -- 7. Tendinopathy -- 8. Polyneuropathy -- 9. Cognitive Function -- 10. Depression/Suicide -- THERAPEUTIC INTERVENTION -- Coenzyme Q10 -- L-Carnitine -- DISCUSSION -- CONCLUSION -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 3 PRELIMINARY FINDINGS ABOUT THE TRENDS OF THE RENAL HEMODYNAMICS AND THE PROXIES OF CARDIOVASCULAR RISK DURING A SHORT COURSE OF ATORVASTATIN THERAPY IN ESSENTIAL HYPERTENSIVES -- ABSTRACT -- INTRODUCTION -- SUBJECTS AND METHODS -- a) Patients -- b) Study Design -- c) Parameters Evaluated. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | d) Assessment of the renal hemodynamical parameters -- e) Statistical Analysis -- RESULTS -- DISCUSSION -- APPENDIX -- Determination of the Inulin: -- a) Serum -- b) Urine -- Determination of the p-Aminohippurate: -- a) Serum -- b) Urine -- REFERENCES -- Chapter 4 BENEFICIAL EFFECTS OF THE ADDITION OF FENOFIBRATE TO STATIN THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER PERCUTANEOUS CORONARY INTERVENTIONS -- ABSTRACT -- INTRODUCTION -- RESEARCH DESIGN AND METHODS -- RESULTS -- DISCUSSION -- CONCLUSIONS -- REFERENCES -- Chapter 5 NON-LIPID LOWERING EFFECTS OF STATINS -- ABSTRACT -- PLEIOTROPIC EFFECTS OF STATINS -- PROLIFERATION, MIGRATION AND APOPTOSIS -- STATINS STABILIZE ATHEROSCLEROTIC PLAQUE BY ENZYME INHIBITION -- ANTI-INFLAMMATORY PROPERTIES -- IMMUNOMODULATING PROPERTIES -- STATIN-MEDIATED PROMOTION OF METABOLIC PATHWAYS -- STATINS PREVENT LDL-PROTEOGLYCAN INTERACTION -- STATINS AND CANCER -- HEMOSTASIS AND THROMBOGENICITY -- STATINS AND RHEUMATOID ARTHRITIS -- STATINS AS ANTI-ARRHYTHMIC THERAPY -- MULTIPLE SCLEROSIS -- CONCLUSIONS -- REFERENCES -- Chapter 6 STATINS IN THE THERAPY OF ACUTE CORONARY SYNDROME -- ABSTRACT -- THE VULNERABLE PLAQUE -- Macrophages -- Endothelium -- Smooth Muscle Cells -- T-lymphocytes -- PLEIOTROPIC EFFECTS OF STATINS -- Anti-Inflammatory Effects of Statins -- Antioxidant Effects of Statins -- Statin Effects on Endothelial Dysfunction -- Statin Effects on Nitric Oxide -- Statins and Endothelin-1 -- Antithrombotic Effects of Statins -- STATINS IN EARLY SECONDARY PREVENTION -- Observational Studies -- Randomized Trials -- STATINS IN THE THERAPY OF ACS -- Animal Studies -- Clinical Studies -- CONCLUSION -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 7 BAD HDL-C RESPONDERS TO STATINS -- ABSTRACT -- INTRODUCTION -- THE FIRST CASE REPORT OF A BAD HDL-C RESPONDER TO STATINS. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | CONFIRMATION ABOUT THE EXISTENCE OF BAD HDL-C RESPONDERS -- Data Recording -- Baseline Values -- Treatment Results -- Bad HDL-C Responders -- The Confirmation about Bad HDL-C Responders to Statins -- THE PREVALENCE OF BAD HDL-C RESPONDERS -- Data Collection -- Baseline Values -- Pharmaceutical Treatment -- Treatment Results -- Low HDL-C Levels -- CAUSES FOR BAD HDL-C RESPONSE -- Epidemiological Evidence on Low HDL-C -- Causes for Low HDL-C -- Secondary to Modifiable Risk Factors -- Some Diseases -- Some Drugs -- Possible Causes for bad HDL-C Response -- Compliance to the Diet -- Myalgia -- Metabolic Pathway -- Genetic Profile -- THE GUIDELINES ABOUT LOW HDL-C -- Methods of the Review -- Selected Guidelines -- Diagnostic Threshold Levels -- Treatment Target Levels -- Management of Low HDL-C -- Recommendations from the Guidelines -- THE TREATMENT OF BAD HDL-C RESPONDERS -- Data Collection -- Bad HDL-Responders -- Crossover Results -- Choice between Statins and Fibrates? -- Review and Critical Appraisal of the RCTs with Fibrates -- Treatment of Low HDL-C -- THE FUTURE RESEARCH ON BAD HDL-C RESPONDERS TO STATINS -- CONCLUSION -- THE IMPACT OF THE RESEARCH -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 8 BENEFICIAL EFFECTS OF STATINS IN SYSTEMIC LUPUS ERYTHEMATOSUS: MOLECULAR MECHANISM INVOLVED -- ABSTRACT -- INTRODUCTION -- MECHANISM OF ACTION OF STATINS -- MITOGEN-ACTIVATED PROTEIN KINASES (MAPKS) PATHWAYS -- STATINS, CARDIOVASCULAR SYSTEM AND MAPKS -- Statins and ERK Cascade -- Statins and p38 MAPK Cascade -- Statins and JNK Cascade -- Immunomodulatory Effects of Statins and Atherosclerosis -- STATINS, IMMUNOLOGIC SYSTEM AND MAPKS -- Effects of Statins in other Rheumatic Diseases -- Animal and In Vitro Studies -- REFERENCES -- INDEX. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Statins (Cardiovascular agents). |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Anticholesteremic agents. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Holmqvist, Gunnar N. |
| Title | Statins: Indications and Uses, Safety and Modes of Action |
| Place, publisher, and date of publication | Hauppauge : Nova Science Publishers, Incorporated,c2008 |
| International Standard Book Number | 9781606921036 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3018501">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3018501</a> |
| Public note | Click to View |
No items available.